FDA-Approved Drug Library Mini
Cat. No. : | CS-L022M | (2772 compounds) |
---|
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.
MCE owns a unique collection of 2772 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.
Size (Pre-dissolved DMSO) | Stock | Price |
---|---|---|
10 μL/well (10 mM solution) | In-stock | Get quote |
Data Sheet
Description & Advantages
Composition
Contents
Formulation: | A collection of 2772 marketed drugs supplied as pre-dissolved Solutions |
---|---|
Container: | 96-well Plate With Peelable Foil Seal |
Storage: | -80°C |
Shipping: | Blue ice |
Customize Your Library
You can select:- Specific Compounds
- Quantities
- Plate map
- Concentration
- Format (Solid or DMSO Solution)
Please contact us at sales@chemscene.com